An exemplar population-based study to predict up-take of non-intensive therapies in acute myeloid leukaemia

TY - JOUR

T1 - An exemplar population-based study to predict up-take of non-intensive therapies in acute myeloid leukaemia

AU - Ip, Keith

AU - Bedair, Khaled

AU - Tauro, Sudhir

N1 - Crown Copyright © 2020 Published by Elsevier Ltd. All rights reserved.

PY - 2020/5

Y1 - 2020/5

N2 - Recent advances in non-intensive therapy (non-IC) have demonstrated the potential for improved outcomes in patients with non-promyelocytic acute myeloid leukaemia (AML) unsuitable for intensive chemotherapy [1]. These data are mainly derived from clinical trial participants and therefore numbers of unselected patients that could benefit from novel agents are unknown. Identifying factors that influence treatment decisions in unselected patients would be useful to predict up-take of non-IC. A previous study on Medicare beneficiaries has identified variables influencing intensive treatment in older AML patients, but not the reasons for favouring SC over non-IC [2]. As the use of non-IC in patients increases [3], predicting the size of the target population for non-IC, identifying barriers to therapy and the determinants of survival in ‘real-world’ patients will help budgetary planning and patient outcomes. In the absence of a national registry of AML patients in the United Kingdom, through this retrospective study, we aimed to identify the proportion of AML patients that receives non-IC in our catchment population of 450,000, and factors affecting treatment and survival.

AB - Recent advances in non-intensive therapy (non-IC) have demonstrated the potential for improved outcomes in patients with non-promyelocytic acute myeloid leukaemia (AML) unsuitable for intensive chemotherapy [1]. These data are mainly derived from clinical trial participants and therefore numbers of unselected patients that could benefit from novel agents are unknown. Identifying factors that influence treatment decisions in unselected patients would be useful to predict up-take of non-IC. A previous study on Medicare beneficiaries has identified variables influencing intensive treatment in older AML patients, but not the reasons for favouring SC over non-IC [2]. As the use of non-IC in patients increases [3], predicting the size of the target population for non-IC, identifying barriers to therapy and the determinants of survival in ‘real-world’ patients will help budgetary planning and patient outcomes. In the absence of a national registry of AML patients in the United Kingdom, through this retrospective study, we aimed to identify the proportion of AML patients that receives non-IC in our catchment population of 450,000, and factors affecting treatment and survival.

UR - https://www.scopus.com/pages/publications/85082436753

U2 - 10.1016/j.leukres.2020.106348

DO - 10.1016/j.leukres.2020.106348

M3 - Letter

C2 - 32240864

SN - 0145-2126

VL - 92

SP - 1

EP - 3

JO - Leukemia Research

JF - Leukemia Research

M1 - 106348

ER -